Rates of MRD-negative responses and 2-year PFS rates, assessed at landmarks of postinduction, post-ASCT, and postconsolidation time points, in patients achieving CR, uCR, and VGPR
| . | Best response at time point . | P value for comparison . | ||||
|---|---|---|---|---|---|---|
| CR* . | uCR . | VGPR . | CR vs uCR . | uCR vs VGPR . | CR vs VGPR . | |
| MRD assessment | ||||||
| Postinduction, N evaluable | 126 | 69 | 97 | |||
| MRD-negative rate, n (%) | 66 (52%) | 40 (58%) | 15 (15%) | .4 | <.0001 | <.0001 |
| Post-ASCT, N evaluable | 123 | 97 | 105 | |||
| MRD-negative rate, n (%) | 84 (68%) | 76 (78%) | 30 (29%) | .1 | <.0001 | <.0001 |
| Postconsolidation, N evaluable | 103 | 113 | 80 | |||
| MRD-negative rate, n (%) | 78 (76%) | 85 (75%) | 22 (28%) | .9 | <.0001 | <.0001 |
| PFS | ||||||
| From postinduction time point; median follow-up 31.1 mo, N | 129 | 72 | 106 | |||
| 2-y PFS rate (95% CI) | 93% (88-97) | 88% (81-94) | 78% (69-86) | .5 | .001 | .02 |
| From ASCT time point, median follow-up 26.4 mo, N | 133 | 105 | 116 | |||
| 2-y PFS rate (95% CI) | 88% (82-94) | 87% (81-94) | 77% (68-85) | .7 | .05 | .1 |
| From postconsolidation time point, median follow-up 23.5 mo, N | 149 | 118 | 85 | |||
| 2-y PFS rate (95% CI) | 85% (80-96) | 88% (82-95) | 76% (68-85) | .4 | .1 | .3 |
| . | Best response at time point . | P value for comparison . | ||||
|---|---|---|---|---|---|---|
| CR* . | uCR . | VGPR . | CR vs uCR . | uCR vs VGPR . | CR vs VGPR . | |
| MRD assessment | ||||||
| Postinduction, N evaluable | 126 | 69 | 97 | |||
| MRD-negative rate, n (%) | 66 (52%) | 40 (58%) | 15 (15%) | .4 | <.0001 | <.0001 |
| Post-ASCT, N evaluable | 123 | 97 | 105 | |||
| MRD-negative rate, n (%) | 84 (68%) | 76 (78%) | 30 (29%) | .1 | <.0001 | <.0001 |
| Postconsolidation, N evaluable | 103 | 113 | 80 | |||
| MRD-negative rate, n (%) | 78 (76%) | 85 (75%) | 22 (28%) | .9 | <.0001 | <.0001 |
| PFS | ||||||
| From postinduction time point; median follow-up 31.1 mo, N | 129 | 72 | 106 | |||
| 2-y PFS rate (95% CI) | 93% (88-97) | 88% (81-94) | 78% (69-86) | .5 | .001 | .02 |
| From ASCT time point, median follow-up 26.4 mo, N | 133 | 105 | 116 | |||
| 2-y PFS rate (95% CI) | 88% (82-94) | 87% (81-94) | 77% (68-85) | .7 | .05 | .1 |
| From postconsolidation time point, median follow-up 23.5 mo, N | 149 | 118 | 85 | |||
| 2-y PFS rate (95% CI) | 85% (80-96) | 88% (82-95) | 76% (68-85) | .4 | .1 | .3 |
CI, confidence interval.
CR includes patients in stringent CR in the following proportions: post-induction, 64%; post-ASCT, 76%; and postconsolidation, 79%.